Navigation Links
Glenmark Wins Two Prestigious Global Recognitions at SCRIP Awards 2011
Date:11/4/2011

MUMBAI, India, November 4, 2011 /PRNewswire/ --

SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with two global recognitions, for its business excellence and innovative R & D capabilities. At a glittering ceremony in London which was attended by the Who's Who of the world pharmaceutical industry on November 3; Glenmark was presented with 'Best Company in Emerging Markets' & 'Best Overall Pipeline' recognitions for the year 2011.

"On behalf of our 8000 employees worldwide, we are honoured to receive two prestigious distinctions from a reputed organisation like Informa Healthcare, which hosts the SCRIP Awards," said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Limited, who received the awards on behalf of the company.  "We are specially delighted at having bagged the 'Best Overall Pipeline' distinction which is a testimony of our world-class R&D capabilities and an enormous tribute to all our research staff around the world who have committed themselves over many years to the development of our innovative pipeline," he added.

For SCRIP Awards 2011, Glenmark was the only company worldwide to be shortlisted under four categories. 'Executive of the Year - Glenn Saldanha' and 'Licensing Deal of the Year - GBR 500' were the other 2 categories, where Glenmark was nominated for this year's awards.

While announcing the nominations for Glenmark; SCRIP magazine commented:

  • "Glenmark is a leader among the emerging market companies in drug discovery and development and most of its active substances in the pipeline are first-in-Class." *1
  • "Glenmark's achievements over the year included a major deal with Sanofi in Crohn's disease, completing Phase III trials of its first novel product, crofelemer and demonstrated higher sales and profit growth."*2

* 1 SCRIP magazine issue dated Sep 23, 2011  * 2 SCRIP magazine issue dated Sep 16, 2011

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India.  It is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity).  Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis, IBD, etc.] and Pain [neuropathic pain and inflammatory pain].


'/>"/>
SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pars Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R)
2. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. COPAN WASP® Lands at Prestigious Boston Medical Center
5. NxStage Board Member Dr. Barry M. Straube Honored with Prestigious Award from the American Association of Kidney Patients
6. Portrait Plasma Skin Regeneration Resurfaces at Prestigious Symposium
7. ITelagen Named to Prestigious 2011 Inc. 5000 List of Fastest-Growing Companies
8. Upsher-Smith Receives Prestigious DIANA Award for Third Year in a Row
9. Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility
10. Luminex Corporation Wins Prestigious Medical Design Excellence Award
11. Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... clinical grade cell and tissue hypothermic storage and ... Rice , President and CEO, will be presenting at two ... & Renshaw 19 th Annual Global Investment Conference on ... Pacific time). The conference is being held at the New ...
(Date:9/6/2017)... , Sept. 6, 2017  Medical professionals ... and skills while treating their patients. Medical ... experience without involving patients. Simulation provides a ... can carry out procedures, refine techniques and ... Integration of new technology, such as augmented ...
(Date:9/6/2017)... -- NeuroRx, a clinical stage biopharma company developing the first ... been granted Fast Track status by the US Food and ... followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly ... therapy targeting patients who are admitted to Emergency Departments with ... ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Demand generation pioneer ... East-coast edition of MarTech: The Marketing Tech Conference October 2–4, at the Hynes ... 40 speakers — representing such thought-leading companies as JP Morgan Chase, GE ...
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy ... industry-leading compliance software, The Guard®, has helped another long-time client pass their Department ... and properly satisfy the law. , Thanks to the help of the Compliancy ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... campaign, “Humans With Vaginas.” The goal is to ignite conversation via social media ... care products. The brand has declared September “Humans with Vaginas” month, releasing a ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... millions of older Americans at risk of price gouging for their prescription drugs, ... League (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency ...
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take on one ... better one’s life through God. “The Trials I Face to Receive God’s Grace” is ... found a love for writing. Green feels that expressing his feelings through prayer will ...
Breaking Medicine News(10 mins):